



Treatment of Calcium Channel Blocker & Beta Blocker Overdose

A presentation for HealthTrust Members

April 16, 2025



Emily Herring, PharmD
PGY-1 Pharmacy Resident
HCA Tristar Skyline Medical
Center

Preceptor: Deanna Pouliot, PharmD, BCPS
Clinical Pharmacy Manager
Tristar Skyline Medical Center
Nashville, TN





Speaker Disclosures

- Neither the presenter nor her preceptor have conflicts of interests related to this presentation.
- Note: This program may contain the mention of suppliers, brand products, services, or drugs presented in a case study or comparative format using evidence-based research. Such examples are intended for educational and informational purposes only and should not be perceived as an endorsement of any particular supplier, brand, product, service, or drug.
- The content presented is for informational purposes only & is based upon the presenter(s) knowledge & opinion. It should not be relied upon without independent consultation with & verification by appropriate professional advisors. Individuals & organizations shall have sole responsibility for any actions taken in connection with the content herein. HealthTrust, the program presenter(s) & their employers expressly disclaim any & all warranties as to the content as well as any liability resulting from actions or omissions of any individual or organization in reliance upon the content.



Objectives: Pharmacists & Nurses

1. Recall typical clinical presentations of calcium channel and beta blocker overdoses
2. **Identify** appropriate treatment regimens for calcium channel and beta blocker overdoses depending on patient presentation
3. **Recognize** appropriate treatment targets for calcium channel and beta blocker overdoses



Objectives: Pharmacy Technicians

1. **Recall** medications that can precipitate overdose in patients taking calcium channel and beta blockers
2. **Recognize** medications commonly used to treat overdoses
3. **Identify** appropriate dosing of calcium channel blockers, beta blockers and supportive care/antidote medications



Abbreviations

- AC- activated charcoal
- AE- adverse effect
- AMS- altered mental status
- ATP- adenosine triphosphate
- AV- atrioventricular
- BB- beta blocker
- BP- blood pressure
- cAMP- cyclic AMP
- CCB- calcium channel blocker
- DHP- dihydropyridine
- g- grams
- GI- gastrointestinal
- HIET- Hyperinsulinemic euglycemic therapy
- hr- hour
- IR- immediate release
- IV- intravenous
- K- potassium
- kg- kilogram
- Mg- magnesium
- min- minute
- mL- milliliter
- NDHP- non-dihydropyridine
- Ph- phosphorus
- PO- orally
- SA- sinoatrial
- SR- sustained release
- VA-ECMO- venoarterial extracorporeal membrane oxygenation
- WBI- whole bowel irrigation



TOXIDROMES



CCBs: Pharmacology

- Block L-type voltage-gated calcium channels
 - Prevents intracellular calcium influx required for muscle contraction
 - **Decreased contractility**
 - **Negative inotropy, chronotropy, and dromotropy**
 - Decreased insulin secretion in pancreatic β cells
- Specificity by class:
 - Dihydropyridines (amlodipine, nifedipine, nicardipine, nimodipine): **peripheral vascular smooth muscles**
 - Nondihydropyridines (diltiazem, verapamil): **cardiomyocytes**

Source: Alshaya OA, Alhamed A, Althewaibi S, et al. Calcium Channel Blocker Toxicity: A Practical Approach. J Multidiscip Healthc. 2022;15:1851-1862. Published 2022 Aug 30. doi:10.2147/JMDH.S374887

Source: Goldfine CE, Troger A, Erickson TB, Chai PR. Beta-blocker and calcium-channel blocker toxicity: current evidence on evaluation and management. Eur Heart J Acute Cardiovasc Care. 2024;13(2):247-253. doi:10.1093/ehjacc/zuad138



CCBs: Presentation

Hypotension

Bradycardia*

Heart block

Hyperglycemia

AMS

GI symptoms

**May have reflex tachycardia with DHP CCBs*

Onset: within 8 hours (IR), up to 24 hours (SR)


Source: Alshaya OA, Alhamed A, Althewaibi S, et al. Calcium Channel Blocker Toxicity: A Practical Approach. J Multidiscip Healthc. 2022;15:1851-1862. Published 2022 Aug 30. doi:10.2147/JMDH.S374887

Source: Goldfine CE, Troger A, Erickson TB, Chai PR. Beta-blocker and calcium-channel blocker toxicity: current evidence on evaluation and management. Eur Heart J Acute Cardiovasc Care. 2024;13(2):247-253. doi:10.1093/ehjacc/zuad138



BBs: Pharmacology

- Antagonize beta-adrenergic receptors
 - In myocardial cells
 - These receptors are usually stimulated by catecholamines to open L-type calcium channels downstream
 - Entire process is inhibited in the presence of BBs
 - Decreased contractility
 - Negative inotropy, chronotropy, and dromotropy
- Additional effects due to BB heterogeneity



Source: Goldfine CE, Troger A, Erickson TB, Chai PR. Beta-blocker and calcium-channel blocker toxicity: current evidence on evaluation and management. Eur Heart J Acute Cardiovasc Care. 2024;13(2):247-253. doi:10.1093/ehjacc/zuad138



BBs: Additional Activity

- Nonselective (B1/B2 blockade): carvedilol, labetalol, propranolol, sotalol, nadolol, pindolol
- Selective (B1 blockade): atenolol, metoprolol, esmolol, bisoprolol, acebutolol, betaxolol
- Block Na channels: carvedilol, propranolol, acebutolol
- Block K channels: sotalol, acebutolol
- Block Ca channels: carvedilol, betaxolol
- Block alpha receptors: labetalol, carvedilol
- Beta receptor agonists: acebutolol, pindolol
- Highly lipophilic: propranolol

Source: Goldfine CE, Troger A, Erickson TB, Chai PR. Beta-blocker and calcium-channel blocker toxicity: current evidence on evaluation and management. Eur Heart J Acute Cardiovasc Care. 2024;13(2):247-253. doi:10.1093/ehjacc/zuad138



BBs: Additional Activity + Presentation

- Block Na channels: QRS prolongation
- Block K channels: QTC prolongation
- Block Ca channels: Vasodilation
- Block alpha receptors: Vasodilation
- Beta receptor agonists: Vasodilation
- Highly lipophilic: CNS penetration

Source: Goldfine CE, Troger A, Erickson TB, Chai PR. Beta-blocker and calcium-channel blocker toxicity: current evidence on evaluation and management. Eur Heart J Acute Cardiovasc Care. 2024;13(2):247-253. doi:10.1093/ehjacc/zuad138



BBs: Presentation

Hypotension

Bradycardia

Heart block

Hypoglycemia

AMS

Onset: within 6 hours (IR), up to 24 hours (SR, sotalol)

Source: Goldfine CE, Troger A, Erickson TB, Chai PR. Beta-blocker and calcium-channel blocker toxicity: current evidence on evaluation and management. Eur Heart J Acute Cardiovasc Care. 2024;13(2):247-253. doi:10.1093/ehjacc/zuad138



Evaluation

History/physical

Laboratory

- Electrolytes
- Glucose
- Renal function
- Co-ingestions
- Arterial blood gas

Electrocardiogram/echocardiogram

CCB vs. BB overdose


- Glucose
- Similar presentations, similar treatment



TREATMENT: EARLY ASYMPTOMATIC PATIENTS



Treatment Algorithm





GI Decontamination

Activated charcoal

- If within 1-2 hours post-ingestion
- 50-100g PO x1, with or without sorbitol
- Avoid if AMS, nausea, or vomiting

Whole bowel irrigation

- If large amount of SR product
- Polyethylene glycol 1.5-2 L/hr through OG tube
- Continue until effluent is clear

- Not commonly used
- Observation for ~24 hours despite treatment chosen

Sources: Alshaya OA, Alhamed A, Althewaibi S, et al. Calcium Channel Blocker Toxicity: A Practical Approach. J Multidiscip Healthc. 2022;15:1851-1862. Published 2022 Aug 30. doi:10.2147/JMDH.S374887

Source: Goldfine CE, Troger A, Erickson TB, Chai PR. Beta-blocker and calcium-channel blocker toxicity: current evidence on evaluation and management. Eur Heart J Acute Cardiovasc Care. 2024;13(2):247-253. doi:10.1093/ehjacc/zuad138


Source: St-Onge M, Anseeuw K, Cantrell FL, et al. Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults. Crit Care Med. 2017;45(3):e306-e315. doi:10.1097/CCM.0000000000002087



TREATMENT: INITIAL OPTIONS FOR SYMPTOMATIC PATIENTS



Treatment Algorithm





Initial Treatment Options

Calcium

Glucagon

IV fluids

Vasoactive
agents

High-dose
insulin

Atropine

Magnesium

Sodium
bicarbonate

Dialysis



Calcium

- Improves **BP** and **contractility**
- Calcium chloride 10%
 - 10-20mL (1-2g) every 10-20 minutes, or
 - 0.2-0.4 mL/kg/hr (0.02-0.04 g/kg/hr)
- Calcium gluconate 10%
 - 30-60mL (3-6g) every 10-20 minutes, or
 - 0.6-1.2 mL/kg/hr (0.06-0.12 g/kg/hr)
- Obtain **ionized calcium concentration** every 30-60 minutes
 - Goal: 1.5X upper limit of normal

Source: Alshaya OA, Alhamed A, Althewaibi S, et al. Calcium Channel Blocker Toxicity: A Practical Approach. J Multidiscip Healthc. 2022;15:1851-1862. Published 2022 Aug 30. doi:10.2147/JMDH.S374887



Glucagon

- **Positive inotropy and chronotropy** (bypasses blocked adrenergic receptors through direct effects on **adenylate cyclase**)
- **Bridges patients** for other treatments
- 5-10mg slow IV push followed by 1-5 mg/hr continuous infusion
 - Available in 1mg vials/syringes
- **AEs-** nausea, vomiting, tachyphylaxis

Source: Graudins A, Lee HM, Druda D. Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies. Br J Clin Pharmacol. 2016;81(3):453-461. doi:10.1111/bcp.12763



IV Fluid Resuscitation

- Improves **hemodynamic stability** in hypotensive patients
- Use early in treatment course
- 10-20 mL/kg of crystalloid
- AEs- **fluid overload**



Vasoactive Agents

- Improve hemodynamic stability
- **High doses** often necessary
 - Norepinephrine >1.25 mcg/kg/min, epinephrine >1 mcg/kg/min

Epinephrine	Norepinephrine	Milrinone	Vasopressin
<ul style="list-style-type: none">• α/β• Improves both bradycardia and hypotension	<ul style="list-style-type: none">• $\alpha>\beta$• Preferred in vasodilatory shock	<ul style="list-style-type: none">• PDE3• Positive inotropy and chronotropy by bypassing adrenergic receptors	<ul style="list-style-type: none">• V1/V2• As an adjunct• Improves hypotension

Source: Alshaya OA, Alhamed A, Althewaibi S, et al. Calcium Channel Blocker Toxicity: A Practical Approach. J Multidiscip Healthc. 2022;15:1851-1862. Published 2022 Aug 30. doi:10.2147/JMDH.S374887

Source: Graudins A, Lee HM, Druda D. Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies. Br J Clin Pharmacol. 2016;81(3):453-461. doi:10.1111/bcp.12763



High-Dose Insulin/HIET

“Hyperinsulinemic euglycemic therapy”

Increases intracellular transport
of glucose to myocardial cells

Positive inotropy

Decreases vasopressor
requirement

May improve survival

Source: Krenz JR, Kaakeh Y. An Overview of Hyperinsulinemic-Euglycemic Therapy in Calcium Channel Blocker and β -blocker Overdose. Pharmacotherapy. 2018;38(11):1130-1142. doi:10.1002/phar.2177




High-Dose Insulin/HIET

- High-dose regular insulin:
 - 1 U/kg bolus, then
 - 1 U/kg/hr up to 10 U/kg/hr
 - Commonly available as 1 U/mL (100 unit) bags, but may need higher concentration or volume
- Administered with **dextrose** as needed for euglycemia
 - Monitor glucose every 30 minutes initially, then every 60 minutes
 - Goal glucose >100 mg/dL
 - Dextrose infusions or high concentration dextrose pushes

Source: Krenz JR, Kaakeh Y. An Overview of Hyperinsulinemic-Euglycemic Therapy in Calcium Channel Blocker and β -blocker Overdose. Pharmacotherapy. 2018;38(11):1130-1142. doi:10.1002/phar.2177



High-Dose Insulin/HIET





Atropine

- Used in symptomatic **bradycardia** and conduction abnormalities
- 0.5-1mg every 3-5 minutes as needed
- Often **ineffective**
 - Could be diagnostic as it will often not work in CCB/BB overdose patients

Source: St-Onge M, Anseeuw K, Cantrell FL, et al. Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults. Crit Care Med. 2017;45(3):e306-e315. doi:10.1097/CCM.0000000000002087



Agent-Specific Treatment

- Sodium channel blockade
 - BBs (carvedilol, propranolol, acebutolol)
 - Widened QRS +/- monomorphic ventricular tachycardia
 - Treatment: **sodium bicarbonate**
- Potassium channel blockade
 - BBs (sotalol, acebutolol)
 - Prolonged QTc interval +/- torsades de pointes
 - Treatment: **magnesium**
- High lipophilicity
 - **Propranolol**
 - **Seizures**
 - Treatment: **benzodiazepines**, additional seizure medications

Source: Goldfine CE, Troger A, Erickson TB, Chai PR. Beta-blocker and calcium-channel blocker toxicity: current evidence on evaluation and management. Eur Heart J Acute Cardiovasc Care. 2024;13(2):247-253. doi:10.1093/ehjacc/zuad138



Dialysis

Used in life-threatening cases

Not recommended for CCB overdose

Only useful in select BB overdose: atenolol, nadolol, acebutolol, and sotalol

HD preferred

Continue until clinical improvement (HR, BP, perfusion, vasopressor requirements)

Source: Bouchard J, Shepherd G, Hoffman RS, et al. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. Crit Care. 2021;25(1):201. Published 2021 Jun 10. doi:10.1186/s13054-021-03585-7


Source: Wong A, Hoffman RS, Walsh SJ, et al. Extracorporeal treatment for calcium channel blocker poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2021;59(5):361-375. doi:10.1080/15563650.2020.1870123



TREATMENT: REFRACTORY TO FIRST-LINE AGENTS



Treatment Algorithm





Refractory Treatment Options

Titration of
current
treatments

IV lipid
emulsion

Methylene
blue

Pacemaker

ECMO



IV lipid emulsion

- **Minimal positive evidence**
- Used in lipophilic medications: **propranolol, verapamil**
- 20% lipid emulsion
 - 1.5 mL/kg once or twice, THEN
 - 0.25 mL/kg/min for 30-60 minutes
 - Maximum total daily dose: 12.5 mL/kg

Source: Lavonas EJ, Akpunonu PD, Arens AM, et al. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2023;148(16):e149-e184. doi:10.1161/CIR.0000000000001161

Source: Alshaya OA, Alhamed A, Althewaibi S, et al. Calcium Channel Blocker Toxicity: A Practical Approach. *J Multidiscip Healthc*. 2022;15:1851-1862. Published 2022 Aug 30. doi:10.2147/JMDH.S374887



IV lipid emulsion

May increase
absorption of
medication still
in the GI tract

May interfere
with laboratory
testing and/or
ECMO

May cause
pancreatitis or
sudden
cardiovascular
collapse

May sequester
other lipophilic
medications
patient is
requiring

Source: Lavonas EJ, Akpunonu PD, Arens AM, et al. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2023;148(16):e149-e184. doi:10.1161/CIR.0000000000001161

Source: Alshaya OA, Alhamed A, Althewaibi S, et al. Calcium Channel Blocker Toxicity: A Practical Approach. *J Multidiscip Healthc*. 2022;15:1851-1862. Published 2022 Aug 30. doi:10.2147/JMDH.S374887



Methylene Blue

- Used in refractory vasodilatory shock
- Nitric oxide synthase inhibitor
- 1-2 mg/kg over 15 minutes followed by 1 mg/kg/hr continuous infusion (maximum 7 mg/kg)
- AEs- blue/green discoloration, methemoglobinemia, hemolytic anemia, arrhythmias, respiratory collapse, serotonin syndrome

Source: Alshaya OA, Alhamed A, Althewaibi S, et al. Calcium Channel Blocker Toxicity: A Practical Approach. J Multidiscip Healthc. 2022;15:1851-1862. Published 2022 Aug 30. doi:10.2147/JMDH.S374887



Pacemaker

- For unstable bradycardia or high-grade AV block
- Capture is often difficult
 - Transvenous more successful than transcutaneous

Source: St-Onge M, Anseeuw K, Cantrell FL, et al. Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults. Crit Care Med. 2017;45(3):e306-e315. doi:10.1097/CCM.0000000000002087



VA-ECMO

“Venoarterial extracorporeal membrane oxygenation”

Used in cardiogenic shock

Allows hemodynamic support while drug is metabolized

AEs- limb ischemia, bleeding, thrombosis

Source: St-Onge M, Anseeuw K, Cantrell FL, et al. Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults. Crit Care Med. 2017;45(3):e306-e315. doi:10.1097/CCM.0000000000002087



SUMMARY



CCB and BB Overdose

- Present with **hypotension and bradycardia**
- Asymptomatic patients should be observed for 24 hours
 - **Activated charcoal** can be given within 1 hour of ingestion
 - **Whole bowel irrigation** can be considered for SR formulations
- **Calcium, glucagon, and IV fluids** can stabilize the patient initially




CCB and BB Overdose

- High doses of **vasoactive agents** are often necessary
 - **Norepinephrine, epinephrine, vasopressin, or milrinone** are preferred
 - Methylene blue can be considered in refractory cases
- **Hyperinsulinemic euglycemic** therapy decreases vasopressor requirements and may improve survival
 - Administer with **dextrose**
- Options for specific populations or refractory treatment include atropine, lipid emulsion, dialysis, VA-ECMO, or pacemaker placement



Treatment Algorithm





ASSESSMENT QUESTIONS: PHARMACISTS & NURSES



Assessment Question 1:

Which of the following best represents the hemodynamic presentation of a calcium channel blocker or beta blocker overdose:

- A. Hypertensive and tachycardic
- B. Normotensive and bradycardic
- C. Hypotensive and bradycardic
- D. Hypotensive and tachycardic



Assessment Question 1: Answer

Which of the following best represents the hemodynamic presentation of a calcium channel blocker or beta blocker overdose:

- ~~A. Hypertensive and tachycardic~~
- ~~B. Normotensive and bradycardic~~
- C. Hypotensive and bradycardic**
- ~~D. Hypotensive and tachycardic~~



Assessment Question 2:

Which of the following options is an appropriate initial treatment regimen of a suspected calcium channel blocker or beta blocker overdose:

- A. Norepinephrine and methylene blue
- B. Glucagon, calcium chloride, and IV fluids
- C. Glucagon, calcium gluconate, and IV lipid emulsion
- D. Hemodialysis



Assessment Question 2: Answer

Which of the following options is an appropriate initial treatment regimen of a suspected calcium channel blocker or beta blocker overdose:

- ~~A. Norepinephrine and methylene blue~~
- B. Glucagon, calcium chloride, and IV fluids**
- ~~C. Glucagon, calcium gluconate, and IV lipid emulsion~~
- ~~D. Hemodialysis~~



Assessment Question 3:

Which of the following would you expect after a patient is treated with first-line options, high-dose insulin, and vasoactive agents:

- A. Decreased blood pressure
- B. Decreased heart rate
- C. Negative inotropy and/or chronotropy
- D. Positive inotropy and/or chronotropy



Assessment Question 3: Answer

Which of the following would you expect after a patient is treated with first-line options, high-dose insulin, and vasoactive agents:

- ~~A. Decreased blood pressure~~
- ~~B. Decreased heart rate~~
- ~~C. Negative inotropy and/or chronotropy~~
- D. Positive inotropy and/or chronotropy**



ASSESSMENT QUESTIONS: PHARMACY TECHNICIANS



Assessment Question 1:

Which of the following medications can cause a calcium channel blocker or beta blocker overdose:

- A. Lisinopril
- B. Amlodipine
- C. Metformin
- D. Furosemide



Assessment Question 1: Answer

Which of the following medications can cause a calcium channel blocker or beta blocker overdose:

~~A. Lisinopril~~

B. Amlodipine

~~C. Metformin~~

~~D. Furosemide~~



Assessment Question 2:

Which of the following medications can be used to treat a calcium channel blocker or beta blocker overdose:

- A. High-dose insulin
- B. Metoprolol
- C. Nicardipine
- D. Nitroglycerin



Assessment Question 2: Answer

Which of the following medications can be used to treat a calcium channel blocker or beta blocker overdose:

A. High-dose insulin

~~B. Metoprolol~~

~~C. Nicardipine~~

~~D. Nitroglycerin~~



Assessment Question 3:

Which of the following options demonstrates an appropriate dosing regimen for the associated treatment:

- A. Glucagon 0.05g once
- B. Calcium gluconate 3g once
- C. Lorazepam 100mg as needed for seizures
- D. Lactated ringers 5 liter bolus once



Assessment Question 3: Answer

Which of the following options demonstrates an appropriate dosing regimen for the associated treatment:

- ~~A. Glucagon 0.05g once~~
- B. Calcium gluconate 3g once**
- ~~C. Lorazepam 100mg as needed for seizures~~
- ~~D. Lactated ringers 5 liter bolus once~~



References

1. Alshaya OA, Alhamed A, Althewaibi S, et al. Calcium Channel Blocker Toxicity: A Practical Approach. J Multidiscip Healthc. 2022;15:1851-1862. Published 2022 Aug 30. doi:10.2147/JMDH.S374887
2. Bouchard J, Shepherd G, Hoffman RS, et al. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. Crit Care. 2021;25(1):201. Published 2021 Jun 10. doi:10.1186/s13054-021-03585-7
3. Goldfine CE, Troger A, Erickson TB, Chai PR. Beta-blocker and calcium-channel blocker toxicity: current evidence on evaluation and management. Eur Heart J Acute Cardiovasc Care. 2024;13(2):247-253. doi:10.1093/ehjacc/zuad138
4. Graudins A, Lee HM, Druda D. Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies. Br J Clin Pharmacol. 2016;81(3):453-461. doi:10.1111/bcp.12763
5. Isbister GK, Jenkins S, Harris K, Downes MA, Isoardi KZ. Calcium channel blocker overdose: Not all the same toxicity. Br J Clin Pharmacol. 2025;91(3):740-747. doi:10.1111/bcp.16258
6. Krenz JR, Kaakeh Y. An Overview of Hyperinsulinemic-Euglycemic Therapy in Calcium Channel Blocker and B-blocker Overdose. Pharmacotherapy. 2018;38(11):1130-1142. doi:10.1002/phar.2177



References

7. Lauterbach M. Clinical toxicology of beta-blocker overdose in adults. Basic Clin Pharmacol Toxicol. 2019;125(2):178-186. doi:10.1111/bcpt.13231
8. Lavonas EJ, Akpunonu PD, Arens AM, et al. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2023;148(16):e149-e184. doi:10.1161/CIR.0000000000001161
9. Routsolias JC, Berg SE, Paloucek FP. Does Glucagon Really Work for Beta Blocker Overdose?. J Med Toxicol. 2023;19(1):7-8. doi:10.1007/s13181-022-00923-1
10. St-Onge M, Anseeuw K, Cantrell FL, et al. Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults. Crit Care Med. 2017;45(3):e306-e315. doi:10.1097/CCM.0000000000002087
11. St-Onge M, Dubé PA, Gosselin S, et al. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol (Phila). 2014;52(9):926-944. doi:10.3109/15563650.2014.965827
12. Wong A, Hoffman RS, Walsh SJ, et al. Extracorporeal treatment for calcium channel blocker poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2021;59(5):361-375. doi:10.1080/15563650.2020.1870123



Thank you!

Emily Herring, PharmD
PGY-1 Pharmacy Resident
emily.herring@hcahealthcare.com



CONFIDENTIAL – Contains proprietary information. Not intended for external distribution.